N/A N=34 Follicular Activation in Poor Responders
Infertility
Primary: Number of Metaphase II (MII) — 4; 2 Oocytes — p=0.302
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=49 Feasibility Study for Development of an Early Test for Ovarian Failure
Healthy · Premature Ovarian Failure
Primary: Follicle Stimulating Hormone Stimulated Serum Inhibin B Levels. — 50.7; 48.8; 96.6; 47.7 participants
Phase 4 N=10 The Role of Estrogen in Luteinizing Hormone Surge and Ovulation
Ovulation Disorder · Ovarian Cysts
Primary: Number of Participants With Progesterone Level Greater Than 1.5 ng/mL — 9; 10 Participants
Phase 4 N=310 Recombinant Follicle Stimulating Hormone (FSH) (Gonal-f®): Use in Ovulation Induction
Ovulation Induction
Primary: Percentage of Participants With a Mono-follicular Development — 56.55; 55.20 percentage of participants — p=0.9560
Phase 4 N=112 Follicular Steroid Genesis in Controlled Ovarian Stimulation
Infertility · Controlled Ovarian Hyperstimulation
Primary: SERUM PROGSTERONE CONCENTRATION — 0.74; 0.45 ng/mL — p=<0.05
Phase 3 N=249 Luteal vs Follicular Surgical Oophorectomy and Tamoxifen in Premenopausal Women With Metastatic Hormone Receptor Positive Breast Cancer
Breast Cancer
Primary: Overall Survival — 2.14; 2.00 years
Phase 4 N=3 Ovulation Trigger With hCG Compared to GnRH Agonist in Patients With Repeated IVF Failures
Infertility
Primary: Fetal Heart Activity 1 Month After Oocyte Retrieval — 0; 0 participants with fetal heart activity
N/A N=71 Serum Levels of C Type Natriuretic Peptide in Different Reproductive Periods
Serum CNP Levels · Healthy Reproductive Age Women · Healthy Perimenopausal Women
Primary: Serum C Type Natriuretic Peptide Levels — 43.68; 55.98; 116.36 pg/ml — p=<0.017
N/A N=201 FOLCROM Trial: Foley Catheter in Rupture of Membranes
Premature Rupture of Membranes
Primary: Time From Induction of Labor Until Delivery — 14.4; 13.9 hours
Phase 4 N=21 Use of High Cost Monitoring During Letrozole Ovulation Induction
Infertility
Primary: Pregnancy Success Rate — 75; 25 percentage of participants
Phase 3 N=52 A Prospective Study to Evaluate the Addition of Subcutaneous Recombinant Human-Luteinizing Hormone With Recombinant Human-Follicle Stimulating Hormone on Follicular Development in Women Undergoing Ovarian Stimulation for Assisted Reproductive Technologies
Infertility · Ovarian Stimulation
Primary: Mean Number of Metaphase II Oocytes Per Participant Who Underwent Ovum Pick up for Intra-cytoplasmic Sperm Injection (ICSI) — 9.5 Metaphase II Oocytes
Phase 4 N=188 Concomitant Administration of FSH With HCG Improves Oocyte Maturation and Quality Double -Blinded Randomized Trial
Infertility
Primary: Mean Fertilization Proportion (2PN/Oocytes Collected) — 0.63; 0.55 proportion of oocytes fertilized
Early Phase 1 N=6 Investigation of Female Reproductive Hormone Dynamics During Adolescence
Menstruation Disturbances
Primary: Ovulation in Cycle 2 — 3; 2 Participants
N/A N=700 Ulipristal Emergency Contraception Used Before or After Ovulation
Contraception
Primary: Percentage of Pregnancies Prevented (PPP) — 77.5; 36.9 percentage of pregnancies prevented — p=<0.0001
N/A N=96 Differential Regulation of VEGF, Cadherin, Angiopietin 2 by Trigger Oocyte Maturation With GnRHa vs hCG in Donors
Vascular Endothelial Growth Factor Overexpression
Primary: VEGF Protein and mRNA Levels — 1395; 1069; 1666 pg/ml — p=<0.001
Phase 4 N=384 Triggering of Final Oocyte Maturation With GnRHa (Buserelin) in GnRH Antagonist Cycles
OHSS (Ovarian Hyperstimulation)
Primary: Frequency of Moderate to Severe OHSS. — 0; 2; 2; 0 participants
N/A N=30 Aspiration of Limited Number of Follicles to Prevent Severe Ovarian Hyperstimulation Syndrome
Infertility
Primary: Number of Participants of Severe Ovarian Hyperstimulation Syndrome — 2; 11 participants
N/A N=288 Analysis of ROM Plus to Detect Rupture of Membranes
Rupture of Amniotic Membranes
Primary: Pregnant Women Positive and Negative for Membrane Rupture Measured Via Clinical Assessment, Chart Review and ROM Plus — 95; 88; 160; 187 participants
Phase 4 N=442 Predictive Factors for Ovarian Stimulation Using a Fixed Daily Dose of 200 IU Recombinant FSH (Study 142003)(P05696)
Infertility
Primary: Total Number of Oocytes — 12.4; 12.1 Number of oocytes
N/A N=11 The Effects of a Prostaglandin Inhibitor on Ovulation and the Menstrual Cycle
Ovulation (Follicular Rupture Yes/no) · Menstrual Cycles (Total Length, Bleeding Days) · Gonadotropin and Ovarian Hormone Levels (FSH, LH, E2, P)
Primary: Menstrual Cycle Length — 28.5; 27.2 Days
N/A N=64 Oral Contraceptive Hormone-free Interval Pituitary/ Ovarian Activity
Hypothalamic-pituitary-ovarian Axis, Gonadotropins, Ethinyl Estradiol, Contraceptive Efficacy
Primary: Follicle-stimulating Hormone — 5.01; 5.86; 6.38 milli international units per milliliter — p=0.88
Phase 2 N=10 Elagolix for Fertility Enhancement Clinical Trial
Endometriosis · Unexplained Infertility
Primary: Number of Live Births — 3; 1 live births
Phase 2 N=666 A Dose-Finding Study to Evaluate Ovarian Function and Vaginal Bleeding in Next Generation Rings (P06109/MK-8175A/MK-8342B-012)
Contraception
Primary: Percentage of Participants With Ovulation Incidence, by Cycle — 0; 0; 0; 0 Percentage of Participants
N/A N=67 Automated Folliculometry Using Five-Dimensional Ultrasound
Automated Folliculometry Using Five-Dimensional Ultrasound
Primary: The Mean Follicular Diameter by Two-Dimensional Ultrasound — 8.41 mm
Phase 1 N=34 Bioequivalence Trial of Liquid Versus Freeze-Dried Pergoveris® in Pituitary Suppressed Healthy Premenopausal Female Subjects
Healthy
Primary: Baseline Corrected Area Under the Concentration-Time Curve From Zero to Last Quantifiable Concentration (AUC 0-t,Adj) for Follicle-Stimulating Hormone (FSH) — 3187.4…
Phase 1 N=24 Rekovelle PK Trial in Chinese Women
Infertility
Primary: Area Under the Serum Concentration-time Curve From Dosing to Infinity (AUC) — 41.3; 62.9; 83.1 h*ng/mL
Phase 3 N=81 Trial to Assess the Clinical Efficacy and Safety of MSJ-0011 in Inducing Ovulation in Anovulatory or Oligo-ovulatory Japanese Women
Anovulation · Oligo-ovulation · Hypothalamic-pituitary Dysfunction
Primary: Percentage of Subjects With Ovulation Mid-luteal Serum Progesterone (P4) Level of Greater Than or Equal (>=) 5 Nanogram Per Milliliter (ng/mL) or Clinical Pregnancy…
N/A N=39 Ovarian Morphology and Theca Cell Androgen Production in Women With Polycystic Ovary Syndrome (PCOS)
Polycystic Ovary Syndrome
Primary: Percent Change of 17-OHP Levels From Baseline — 67; 140 percent change
Phase 2 N=58 Lutropin Alfa in Women at Risk of Poor Response
Ovarian Stimulation
Primary: Number of Oocytes Retrieved — 4.0; 3.5 Oocytes
Phase 3 N=82 Induction of Ovulation With Raloxifene or Clomiphene Citrate in Polycystic Ovarian Syndrome
Polycystic Ovary Syndrome
Primary: Percentage of Participants With Ovulation Detected by Ultrasound — 52.5; 40.4 percentage of participants — p=0.3